



Co-Chairs Lars-Hendrik Röller (Germany) & Zane Dangor (South Africa)

6 July 2021

Members of the VMWG





South Africa

Co-chair: Zane Dangor

Special Advisor to the Minister of International Relations and Development



Germany

Co-chair: Lars Hendrik Röller

Director General for Economic and Financial Policy, German Chancellery



Norway

John Arne Røttingen

Global Health Ambassador, Ministry of Foreign Affairs



Indonesia

Dante Saksono Herbuwono

Vice Minister of Health, MoH



Brazil

Arnaldo Correia de Medeiros

Vice-Minister for Health Surveillance, MoH



South Korea

Lee Kang-ho

Director General, Bureau of Health Industry, Ministry of Health and Welfare



USA

Timothy Manning

National COVID19
Supply Coordinator,
White House



China

Junfeng Mao

Deputy Director General, Department of Industry, Ministry of Industry and Information Technology



India

M. K. Aggarwal

Additional Commissioner, UIP, MoH&FW



Saudi Arabia

Abdullah Assiri

Assistant Deputy Minister, Preventive Health, MoH



Rwanda

Theophile Dushime

Special Advisor to the Minister of Health

COVAX
Manufacturing
Taskforce

- Richard Hatchett, CEO of CEPI
- Soumya Swaminathan, Chief Scientist of WHO
- Seth Berkley, CEO of GAVI

ACT-A Hub

- Bruce Aylward, Head of ACT-A Hub
- Usman Mushtaq, Senior Technical Lead



ACT-A Council VMWG Objectives | Support COVAX Taskforce by addressing political bottlenecks and barriers

- Address supply chains for raw materials and vaccines
- Identify and address all barriers, including legal and political, to utilize existing and new production capacities in LMIC
- Facilitate identification of under-utilized/idle capacity for viral vector, mRNA and other Vx technologies
- Facilitate solutions for tech transfer of approved products
- Unlock political barriers for increased manufacturing at the regional level
- Increase information availability on Vx production and deliveries
- Increase transparency on the affordability of vaccines, encourage Vx supplied to COVAX AMC are priced at the cost of goods and production
- Increase political dialogue and build global political consensus



Asks by COVAX Manufacturing Taskforce (1st meeting 22 June)

Workstream	Area of work
1 Improve input supply availability	(a) Create awareness within local manufacturer and supplier community to encourage joining input supply marketplace after MVP launch
	(b) Support discussions with WCO and WTO to significantly accelerate expediting customs processes on critical input supplies
	(c) Facilitate rapid creation of needed bilateral agreements to ease import-export of input supplies on key routes
2 Maximize mid-term manufacturing capacity	(a) Postpone shift to single dose until we have brought the acute phase of the pandemic under control
	(b) Create awareness within local Vx manufacturer community and encourage reaching out to CEPI with F&F capacity needs and underutilized capacity
	(c) Lift any travel restrictions for critical workers
3 New and expanded sustainable capacity in LMICs	(a) Encourage approved tech holders to participate with their technology to the hub network being created (and facilitate licensing to all LMIC regions
	(b) Support to coalesce and integrate parallel initiatives that could benefit from this effort (to receive technology, benefit from sustainable intra-pandemic support, etc.)
	(c) Support program and in-country resourcing needs

Way of working and next steps



- WG to meet fortnightly with COVAX TF and as WG alone
- Next discussion with the COVAX TF later today, co-chairs have requested following focus:
 - Data on global evidence base on current vaccine production capacity
 - Overview other initiatives on vaccine manufacturing
 - Deep-dive on Workstream #3 (long-term capacity, Hub-model)
- Develop working plan of WG
- Chairs plan to hold round table with global industry
- Chairs plan to invite other initiatives on vaccine manufacturing
- Reporting Chairs report to Facilitation Council
- As requested at the last G20 meeting the Chairs will **report to the G20 Summit in Rome** (Oct 30-31) and will do so the same **when required to other plurilateral and multilateral bodies**